Shire: a tempting buy-out bet
Shire: a tempting buy-out bet
Pharmaceuticals firm Shire is set to be taken over – but it’s cheap even if the deal fails.
20 Jul 2018
If you’d invested in: Dechra Pharmaceuticals and Shire
If you’d invested in: Dechra Pharmaceuticals and Shire
Dechra Pharmaceuticals is a drugs company that specialises in the development of medical treatments for pets. Over the next three years, the firm’s ea…
1 Dec 2017
Three stocks to profit from the boom in pharma M&A
Three stocks to profit from the boom in pharma M&A
Ailsa Craig picks three stocks that should capitalise on the M&A trend in the pharmaceutical sector, either as potential targets or as well-establishe…
31 Mar 2017
Pocket some grey pounds – three healthcare stocks to buy now
Pocket some grey pounds – three healthcare stocks to buy now
The ageing population is an opportunity for the health and medical sector. Here, professional investor Garry White picks three healthcare stocks to bu…
7 Sep 2015
Shire’s $30bn move on Baxalta
Shire’s $30bn move on Baxalta
Pharma giant Shire has made an unsolicited $30bn all-share offer for America’s Baxalta.
6 Aug 2015
America's clampdown on tax inversions
America's clampdown on tax inversions
The US government has issued new rules making it harder for American companies to cut their tax bill by relocating their headquarters.
25 Sep 2014
Shire’s stalker raises its offer
Shire’s stalker raises its offer
US pharmaceuticals group AbbVie has made a fourth attempt to bag London-listed Shire Pharmaceuticals.
10 Jul 2014
Subscribe to MoneyWeek and get your first six issues FREE
Subscribe to MoneyWeek now and get your first six magazine issues absolutely FREE
The rise of ‘tax inversion’
The rise of ‘tax inversion’
More and more American businesses are snapping up companies in low-tax countries to make that their official home. British companies are in their sigh…
27 Jun 2014